TY  - JOUR
AU  - Kokanov, Nikola
AU  - Jovanović-Ćupić, Snežana
AU  - Šiljić, Marina
AU  - Ćirković, Valentina
AU  - Petrović, Nina
AU  - Kožik, Bojana
AU  - Krajnović, Milena
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12051
AB  - Variations in the hepatitis C virus (HCV) core sequence have been related to disease progression and response to antiviral therapy. Previously we showed that the methylation status of RASSF1A and p16 genes, and IL28B genotypes affects the response to pegylated interferon/ribavirin (PEG-IFN/RBV) therapy. Herein we investigated whether amino acid (aa) substitutions in the HCV core region alone or in combination with IL28B genotypes and RASSF1A/p16 methylation affect the response to PEG-IFN/RBV therapy and liver disease progression. Among 29 examined patients, we found no association between single aa substitutions and response to therapy. However, we observed that patients with the HCV core aa substitution at position 75 and CT/TT IL28B genotypes were non-responders (NR), (P=0.023). Moreover, these patients had unmethylated RASSF1A. In contrast, most patients (75%) with aa substitutions at position 91 and CC IL28B genotype achieved sustained virologic response (SVR), (P=0.030), and 70% of them had methylated RASSF1A gene. Our results suggest that combined analysis of aa substitutions in the core protein, the IL28B rs12979860 polymorphism, and the methylation status of the RASSF1A gene may help in predicting treatment response to PEG-IFN/RBV in genotype 1b chronic hepatitis C patients.
T2  - Archives of Biological Sciences
T1  - Variability of the HCV core region and host genetic and epigenetic factors can predict the response to pegylated interferon/ribavirin therapy in genotype 1b hepatitis C patients from Serbia
VL  - 75
IS  - 3
SP  - 251
EP  - 262
DO  - 10.2298/ABS230316020K
ER  - 

@article{
author = "Kokanov, Nikola and Jovanović-Ćupić, Snežana and Šiljić, Marina and Ćirković, Valentina and Petrović, Nina and Kožik, Bojana and Krajnović, Milena",
year = "2023",
abstract = "Variations in the hepatitis C virus (HCV) core sequence have been related to disease progression and response to antiviral therapy. Previously we showed that the methylation status of RASSF1A and p16 genes, and IL28B genotypes affects the response to pegylated interferon/ribavirin (PEG-IFN/RBV) therapy. Herein we investigated whether amino acid (aa) substitutions in the HCV core region alone or in combination with IL28B genotypes and RASSF1A/p16 methylation affect the response to PEG-IFN/RBV therapy and liver disease progression. Among 29 examined patients, we found no association between single aa substitutions and response to therapy. However, we observed that patients with the HCV core aa substitution at position 75 and CT/TT IL28B genotypes were non-responders (NR), (P=0.023). Moreover, these patients had unmethylated RASSF1A. In contrast, most patients (75%) with aa substitutions at position 91 and CC IL28B genotype achieved sustained virologic response (SVR), (P=0.030), and 70% of them had methylated RASSF1A gene. Our results suggest that combined analysis of aa substitutions in the core protein, the IL28B rs12979860 polymorphism, and the methylation status of the RASSF1A gene may help in predicting treatment response to PEG-IFN/RBV in genotype 1b chronic hepatitis C patients.",
journal = "Archives of Biological Sciences",
title = "Variability of the HCV core region and host genetic and epigenetic factors can predict the response to pegylated interferon/ribavirin therapy in genotype 1b hepatitis C patients from Serbia",
volume = "75",
number = "3",
pages = "251-262",
doi = "10.2298/ABS230316020K"
}

Kokanov, N., Jovanović-Ćupić, S., Šiljić, M., Ćirković, V., Petrović, N., Kožik, B.,& Krajnović, M.. (2023). Variability of the HCV core region and host genetic and epigenetic factors can predict the response to pegylated interferon/ribavirin therapy in genotype 1b hepatitis C patients from Serbia. in Archives of Biological Sciences, 75(3), 251-262.
https://doi.org/10.2298/ABS230316020K

Kokanov N, Jovanović-Ćupić S, Šiljić M, Ćirković V, Petrović N, Kožik B, Krajnović M. Variability of the HCV core region and host genetic and epigenetic factors can predict the response to pegylated interferon/ribavirin therapy in genotype 1b hepatitis C patients from Serbia. in Archives of Biological Sciences. 2023;75(3):251-262.
doi:10.2298/ABS230316020K .

Kokanov, Nikola, Jovanović-Ćupić, Snežana, Šiljić, Marina, Ćirković, Valentina, Petrović, Nina, Kožik, Bojana, Krajnović, Milena, "Variability of the HCV core region and host genetic and epigenetic factors can predict the response to pegylated interferon/ribavirin therapy in genotype 1b hepatitis C patients from Serbia" in Archives of Biological Sciences, 75, no. 3 (2023):251-262,
https://doi.org/10.2298/ABS230316020K . .